| ŽÁČKOVÁ, Daniela, Hana KLAMOVA, Petra BELOHLAVKOVA, Lukas STEJSKAL, Tereza NEČASOVÁ, Lukáš SEMERÁD, Barbora WEINBERGEROVÁ, Dana SRBOVA, Jaroslava VOGLOVA, Petra ČIČÁTKOVÁ, Zuzana ŠUSTKOVÁ, Tomáš HORŇÁK, Jana BARANOVÁ, Jiřina PROCHÁZKOVÁ a Jiří MAYER. Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. LEUKEMIA & LYMPHOMA. LONDON: TAYLOR & FRANCIS, 2021, roč. 62, č. 1, s. 194-202. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.1080/10428194.2020.1827242. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1695400,
author = {Žáčková, Daniela and Klamova, Hana and Belohlavkova, Petra and Stejskal, Lukas and Nečasová, Tereza and Semerád, Lukáš and Weinbergerová, Barbora and Srbova, Dana and Voglova, Jaroslava and Čičátková, Petra and Šustková, Zuzana and Horňák, Tomáš and Baranová, Jana and Procházková, Jiřina and Mayer, Jiří},
article_location = {LONDON},
article_number = {1},
doi = {http://dx.doi.org/10.1080/10428194.2020.1827242},
keywords = {Chronic myeloid leukemia; chronic phase; imatinib; dasatinib; second line; daily clinical practice},
language = {eng},
issn = {1042-8194},
journal = {LEUKEMIA & LYMPHOMA},
title = {Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice},
url = {https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1827242},
volume = {62},
year = {2021}
}
TY - JOUR
ID - 1695400
AU - Žáčková, Daniela - Klamova, Hana - Belohlavkova, Petra - Stejskal, Lukas - Nečasová, Tereza - Semerád, Lukáš - Weinbergerová, Barbora - Srbova, Dana - Voglova, Jaroslava - Čičátková, Petra - Šustková, Zuzana - Horňák, Tomáš - Baranová, Jana - Procházková, Jiřina - Mayer, Jiří
PY - 2021
TI - Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice
JF - LEUKEMIA & LYMPHOMA
VL - 62
IS - 1
SP - 194-202
EP - 194-202
PB - TAYLOR & FRANCIS
SN - 10428194
KW - Chronic myeloid leukemia
KW - chronic phase
KW - imatinib
KW - dasatinib
KW - second line
KW - daily clinical practice
UR - https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1827242
L2 - https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1827242
N2 - To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients withBCR-ABL1transcript level <= 10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.
ER -
ŽÁČKOVÁ, Daniela, Hana KLAMOVA, Petra BELOHLAVKOVA, Lukas STEJSKAL, Tereza NEČASOVÁ, Lukáš SEMERÁD, Barbora WEINBERGEROVÁ, Dana SRBOVA, Jaroslava VOGLOVA, Petra ČIČÁTKOVÁ, Zuzana ŠUSTKOVÁ, Tomáš HORŇÁK, Jana BARANOVÁ, Jiřina PROCHÁZKOVÁ a Jiří MAYER. Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. \textit{LEUKEMIA \&{} LYMPHOMA}. LONDON: TAYLOR \&{} FRANCIS, 2021, roč.~62, č.~1, s.~194-202. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.1080/10428194.2020.1827242.
|
